Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio ...

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vertex Pharmaceuticals Incorporated ( VRTX) TD Cowen 46th Annual Health Care Conference March 3, 2026 9:10 AM EST ...
The Boston Globe

Vertex falls after FDA doubts broad use of chronic pain drug

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
FierceBiotech

Vertex files FDA approval ask for next-gen cystic fibrosis candidate, resumes diabetes cell therapy trial

Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
Nasdaq

Vertex (VRTX) Gets Positive CHMP Opinion for Kaftrio Expanded Use

Vertex Pharmaceuticals VRTX announced that its triple combination cystic fibrosis (CF) therapy, Kaftrio,has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) ...
The Motley Fool

Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...